Searchable abstracts of presentations at key conferences in endocrinology

ea0056p963 | Male Reproduction | ECE2018

Hypogonadism and mortality in type 2 diabetic men

Corrales Juan Jose , Herrero Ana , Caceres Rocio , Sanchez Ana Isabel , Marcos Miguel , Recio Jose Maria , Miralles Jose Manuel

Introduction: Low testosterone serum levels are associated with increased mortality in non-diabetic males. However, knowledge about the association between male hypogonadism and mortality among type 2 diabetic (T2DM) men is limited due to short follow-up periods in the few existing studies.Objective: To assess the association between hypogonadism and mortality in diabetic men.Material and methods: 263 unselected men with T2DM (mean...

ea0056p1093 | Thyroid (non-cancer) | ECE2018

Should tocilizumab be a second-line treatment of active, moderate-to-severe Graves’ Orbitopathy?

Caceres Rocio , Herrero Ana , Recio-Cordova Jose Maria , Sanchez-Marcos Ana , Higueruela Cecilia , Beaulieu Myriam , Iglesias Rosana , Robles Cristina , Garcia-Duque Maria , Corrales-Hernandez Juan Jose

Introduction: GravesÂ’ orbitopathy (GO) is the most common extrathyroidal manifestation of GravesÂ’ disease. The first-line treatment are intravenous corticoids in active moderate-severe GO. Tocilizumab is a humanized monoclonal antibody against the IL-6 receptor which has been approved for the treatment of rheumatoid arthritis and is in its research stage for patients with corticosteroid-refractory GO.Objectives: To assess the experience with to...

ea0081p771 | Late-Breaking | ECE2022

SRSF6 (Serine/arginine-Rich Splicing Factor 6) is a novel factor regulating androgen receptor signalling in prostate cancer cells

Montero-Hidalgo Antonio J. , Manuel Jimenez-Vacas Juan , de la Salud De la Rosa-Herencia Ana , Herrero-Aguayo Vicente , Gomez-Gomez Enrique , Carlos Fuentes-Fayos Antonio , David Gahete-Ortiz Manuel , Miguel Luque-Huertas Raul

Prostate cancer (PCa) represents the most diagnosed tumour pathology in developed countries among men population. The main pharmacological approach to treat this pathology is based on the blockade of the androgen receptor signalling pathway, commonly known as androgen-deprivation therapy. However, some of the patients does no longer respond to this therapy, therefore developing castration-resistant prostate cancer (CRPC), the most aggressive phenotype of this pathology, which ...

ea0056gp145 | Neuroendocrinology | ECE2018

Hyponatremia-associated mortality and volemia in patients on parenteral nutrition: a prospective multicenter study

Buigues Ana Ortola , Hoyos Emilia Gomez , Garcia Maria Dolores Del Olmo , Ruiz Ana Herrero , Hernandez Julia Alvarez , Perez Cristina Tejera , Antolin Sandra Herranz , Lesmes Irene Breton , Olmos Miguel Angel Martinez , Roman Daniel De Luis

Introduction: In patients receiving Parenteral Nutritcion (PN), hyponatremia is associated with increased in-hospital mortality. Our objective was to evaluate the influence of volemic classification (hypovolemia, euvolemia or hypervolemia) on in-hospital mortality in patients receiving PN presenting hyponatremia.Methods: Prospective, non-interventional, multicenter study in 19 Spanish hospitals. 543 non-critical patients receiving PN were recruited. Hypo...